CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma: Moreover, our present data also suggested that ratio of CD25 expression among TILs might be a biomarker for Tregs‐targeting immunotherapy such as mogamulizumab (humanized anti‐CCR4 antibody), which is one of the most effective systemic therapies for relapsed CTCL.2, 21